Abstract In order to improve the positional adaptability of our previously reported naphthyl diaryltriazines (NP-DATAs), synthesis of a series of novel biphenyl-substituted diaryltriazines (BP-DATAs) with a flexible side chain attached at the C-6 position is presented. These compounds exhibited excellent potency against wild-type (WT) HIV-1 with EC 50 values ranging from 2.6 to 39 nmol/L and most of them showed low nanomolar anti-viral potency against a panel of HIV-1 mutant strains. Compounds 5j and 6k had the best activity against WT, single and double HIV-1 mutants and reverse transcriptase (RT) enzyme comparable to two reference drugs (EFV and ETR) and our lead compound NP-DATA (1). Molecular Abbreviations: AIDS, acquired immunodeficiency syndrome; BP-DATA, biphenyl-substituted diaryltriazine; CC 50 , 50% cytotoxicity concentration; DAPY, diarylpyrimidine; DATA, diaryltriazine; EFV, efavirenz; ETR, etravirine; EC 50 , the concentration causing 50% inhibition of antiviral activity; HEPT, 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine; HIV, human immunodeficiency virus; MD, molecular dynamic; NNRTI, non-nucleoside reverse transcriptase inhibitor; NNIBP, non-nucleoside inhibitor binding pocket; NP-DATA, naphthyl diaryltriazine; NVP, nevirapine; PK, pharmacokinetics; RPV, rilpivirine; RMSD, root-mean square deviation; RT, reverse transcriptase; SAR, structureeactivity relationship; SI, selectivity index; TSAO, tert-butyldimethylsilyl-spiroaminooxathioledioxide; WT, wild-type. *Corresponding authors. Tel./fax: þ86 21 65643811. E-mail addresses: mgfudan@fudan.edu.cn (Ge Meng), rfchen@fudan.edu.cn (Fener Chen). y These authors made equal contributions to this work. modeling disclosed that the side chain at the C-6 position of DATAs occupied the entrance channel of the HIV-1 reverse transcriptase non-nucleoside binding pocket (NNIBP) attributing to the improved activity. The preliminary structureeactivity relationship and PK profiles were also discussed.
Introduction
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are the crucial components of the highly active antiretroviral therapy (HAART) to treat acquired immunodeficiency syndrome (AIDS) caused by human immune deficiency virus 1 (HIV-1) 1, 2 . To date, more than 60 types of structure skeletons have been reported as NNRTIs 3e5 , sharing the advantages of high potency, low toxicity and exquisite selectivity, and favorable pharmacokinetics for targeting at the allosteric non-nucleoside binding pocket (NNIBP) of the reverse transcriptase (RT) 6, 7 . This site is located 10-15 Å away from the active catalytic site of DNA polymerase of HIV-1 RT 8 , which is composed of three main portions including an entrance channel (Lys101, Lys 103, Glu138, Val179, etc.), a groove site (Val106, His235, Pro236, Pro226, Pro225, Phe227, etc.) and a tunnel site (Trp229, Tyr188, Tyr181, etc.) 9e11 . The binding conformations of these various NNRTIs within NNIBP are different, e.g., "butterfly" for 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymines (HEPTs) and nevirapine (NVP) 12 , "seahorse" for diaryltriazines (DATAs) 13 , "horseshoe" for diarylpyrimidines (DAPYs) and "dragon" for the tertbutyldimethylsilyl-spiroaminooxathioledioxide (TSAO) 14 . Thus, the variety and binding conformations could offer many opportunities for further structural optimizations 15, 16 . As an important category of NNRTIs, DATAs share many similarities with DAPYs in their structural skeletons 17e19 , biological activities and structureeactivity relationships (SARs), especially in their flexible binding conformations to suit the allosteric NNIBP 20 . The adaptability could allow them, as well as two clinically used DAPYs (etravirine, ETR; rilpivirine, RPV) 19, 21 , to interact with the variable residues of NNIBP 19 , making these compounds highly effective against wild-type (WT) and various mutant strains of HIV-1 13 . Nevertheless, the emerging drug resistance and the poor aqueous solubility of ETR (much lower than 1 mg/mL) and RPV (20 ng/mL at pH 7.0) inevitably limit the long-term clinical uses 22, 23 .
Based on a 3D-QSAR study of DATAs, our research group has conducted to attach a substituted (a or b)-naphthyl group to the 4-position of DATAs (NP-DATA, 1) 19 and the pep stacking interactions with the aromatic residues in the tunnel site of NNIBP was increased 24À26 . In addition, introducing the biphenyl group to DAPYs have also been disclosed in our lab to increase the pep stacking interactions and antiviral activity 27e29 . Considering the structural similarity between DAPYs and DATAs, we hypothesized that introducing the biphenyl group at a similar position of DATAs might benefit their biological activity. On the other hand, the chemical space around the 6-position of DATAs, which is located at the entrance channel of HIV-1 RT, remains unexplored.
Many kinds of modifications around the channel have been reported, making the target molecules improve antiviral activities as well as physicochemical properties 30 . The modifications commonly introduced some N-containing heterocycles, including both hydrogen-bond donors and acceptors, could increase the interactions with the possible mutants, such as K103N and E138K.
In this study, we designed a new series of DATAs with the purpose to improve the positional adaptability in the NNIBP (Fig. 1) . Firstly, replacement of the naphthyl by biphenyl group at the 4-position through hybridization with biphenyl substituted-DAPY (2) could adapt the hydrophobic pocket of Trp229 and keep the pep stacking interactions with the aromatic residues in the tunnel site of NNIBP. Secondly, attaching the same 4-cyano phenyl amino group of ETR and RPV to the 2-position of DATAs maintains the binding with solvent-exposed area of NNIBP. In this study, the 4-cyano-biphenyl group and 4-cyanoaniline group, which have been determined to be favorable for the activity in our other studies 27e29 are constant in the final BP-DATA molecules. Thirdly and most importantly, introducing the different side chains at the 6-position of DATAs improves the ligand's adaptability with the entrance channel of NNIBP. Various flexible side chains are tried, such as rigid N-containing heterocycles and aliphatic esters, which could increase the number of rotatable bonds and enhance their adaptability and flexibility for binding to the various mutant types of HIV-1 RT.
Results and discussion

Synthesis of the target molecules
As depicted in Scheme 1, the target molecules were obtained. Briefly, the intermediates 3b or 3b-1 and 3a were synthesized following established procedures 27, 29, 31 . Nucleophilic substitution of 3a with the intermediates 10 or 11 provided the key intermediates 4a or 4b, which were followed by nucleophilic substitution with various substituted amines to give the target compounds 5 or 6. All the new compounds were fully characterized by infrared spectra (IR), high resolution mass spectrum (HRMS), proton nuclear magnetic resonance ( 1 H NMR) spectroscopy and carbon nuclear magnetic resonance ( 13 C NMR) spectroscopy.
Biological assays
Anti-HIV activities in cells and SAR analysis
The anti-viral activity of all the target molecules against WT HIV-1 and ROD, as well as their activities against the HIV-1 mutant strains, were evaluated to validate our hypothesis and investigate the preliminary SAR of these DATAs. The antiviral potency of all the target compounds was evaluated using HIV infected MT-4 cells. NVP, EFV and ETR were selected as the reference drugs. The values of EC 50 (anti-HIV potency), CC 50 (cytotoxicity) and SI (selectivity index, CC 50 /EC 50 ratio) were summarized in Tables 1  and 2 , respectively. The biological assay results indicated that all the new DATAs exhibited significant anti-viral potency against WT HIV-1 with low nanomolar EC 50 values of 2.6e39 nmol/L, which were more potent than NVP (EC 50 Z 45 nmol/L) and lead DATA 1 (EC 50 Z 9.3 nmol/L). Compound 6k was the most potent with an EC 50 of 2.6 nmol/L, similar to ETR (EC 50 Z 2.2 nmol/L) and EFV (EC 50 Z 1 nmol/L). Furthermore, compound 6e with a similar activity (EC 50 Z 3.1 nmol/L) showed the lowest cytotoxicity (CC 50 > 125 mmol/L) and the highest selectivity index (SI > 40,000), which was superior to ETR (CC 50 > 2.0 mmol/L, SI > 909). Most of the target compounds showed excellent selectivity against the HIV-2 strain, except compound 5j (EC 50 Z 50 nmol/L).
SAR analysis indicated that: (1) as expected, the biphenyl and p-cyanoaniline groups were favorable to enhance the anti-viral activity. (2) The oxygen and nitrogen linker showed influence on the antiviral activity against HIV-1 and HIV-2 strains. The activity of the compounds with the nitrogen linker was better, for instance, 5b with oxygen linker (EC 50 Z 39 nmol/L) vs. 6c with nitrogen linker (EC 50 Z 11 nmol/L), 5k vs. 6n. The inhibitory activities (EC 50 values) against HIV-2 (ROD) of DATAs with the oxygen linker (eOe in 5a-5k) seemed more potent than the compounds with the nitrogen linker (eNHe in 6a-6n). (3) Compounds 5j and 6m with two more methylenes showed 10-fold and 2-fold higher activity than corresponding 5e and 6g. However, compounds with the methyl piperazine group (5f and 5k, 6h and 6n) exhibited a similar activity. Compounds 5h and 6k with the pyrrolidinol group had an anti-HIV-1 activity higher than those (5g and 6j) with the pyrrolidinylmethanol group. (4) The properties of the substituents (R) at the C6-position of the triazine ring could also exert the dramatic effects on the pharmacological properties of the target compounds. Most compounds have the low cytotoxicity (5a, 5b, 5c, 6a, 6b and 6c) and high SI (6a and 6e), indicating that the substituents at the C6-position could increase their therapeutic safety.
Then, five compounds (5h, 5j, 6e, 6i and 6k) with EC 50 values lower than 3.5 nmol/L were selected to evaluate against the HIV-1 mutant strains (Table 2) . They were more potent than NVP and comparable to EFV and ETR. Notably, 6k was the most potent inhibitor with the antiviral efficacy against the single mutant equivalent to the potency of ETR. Compound 5j exhibited great activity against the viral, especially the double mutant strains of HIV-1 K103N/Y181C and F227L/V106A with EC 50 values of 34 and 17 nmol/L, respectively.
Anti-HIV RT and RT RNase H activities
In order to validate the binding target of these newly synthesized compounds, the enzymatic assay was performed ( Table 3 ). The results demonstrated that all the compounds displayed the good activity against WT HIV-1 RT with IC 50 values ranging from 0.033 to 0.368 mg/mL. Most compounds had better anti-RT activity (IC 50 < 0.1 mg/mL) than NVP and ETR. Compound 6b showed excellent binding affinity with HIV-1 RT (IC 50 Z 0.033 mg/mL). Then, the effect of the target compounds against HIV-1 RT RNase H was evaluated. Only three compounds (5e, 5i, and 5h) showed slight activity against RNase H sharing a similar structure feature of the oxygen linker. The above results indicated that the newly designed DATA compounds specifically targeted RT NNIBP but not RNase H binding site.
2.3. Pharmacokinetics-associated studies 2.3.1. Solubility and lipophilic efficiency Next, the active compounds 5a, 5j, 6e, 6i and 6k were chosen for further assessment of the certain physicochemical properties. The aqueous solubility, which is important for in vivo dosing formulation and bioavailability 32 , was measured at three different pH values (7.4, 7.0 and 2.0) and fasted state simulated intestinal fluid (FaSSIF) ( Table 4 ). The polar surface areas of the selected compounds are around 200 Å 2 , which are similar to ETR (Table 5 ). All the tested compounds showed better solubility (S Z 14.7-60.6 mg/mL) in FaSSIF than that of ETR (S Z 13.2 mg/mL), suggesting the properties of good solubility in the intestinal environment.
Cytochrome P450 enzymatic inhibitory activity
It is reported that the NNRTIs mainly undergo metabolism via cytochrome P450 oxidative metabolism 33 . Therefore, the in vitro ability to inhibit CYP drug-metabolizing enzymes of the most active compound 5j was evaluated (Table 5) . It displayed no 2.3.3. Determination of plasma protein binding rate Furthermore, 5j was evaluated for its binding ability with human and rat plasma proteins with the dialysis equilibrium method. As shown in Table 6 , the plasma protein binding rates of 5j were higher than 99.9% in human and rat. The result demonstrated that the compound 5j could bind strongly to plasma protein with a relatively low concentration of free drug, which needs for optimization in the future 34 .
In vivo pharmacokinetics study
Considering its good potency against WT and mutant variants, pharmacokinetics (PK) properties of compound 5j were evaluated in SD rats. After a single 2 mg/kg i.v. dose of 5j, the mean clearance rate (CL) and half-time (t 1/2 ) were 5.06 mL/min$kg and 0.734 h, respectively (Table 7 , Fig. 2 and Supporting Information Fig. S1 ). Absorption of 5j was assessed after being orally dosed at 20 mg/kg; it reached maximum concentration (T max ) at 13.3 h with a maximum concentration (C max ) of 43.23 ng/mL. However, the oral bioavailability (F) was only 0.485%, which was very low requiring further modification. All methods and procedures of protocol were approved by the Animal Care and Use Committee of WuXi AppTec (Shanghai site).
Molecular modelling
To further understand the binding modes between these new DATAs and RT, we conducted molecular docking studies of the representative compounds 5j and 6k with Surflex Dock. The X-ray crystal structure of the WT HIV-1 RT (2ZD1) was used for the docking calculations. PyMOL software was used to analyze and visualize these docking results. Compounds 5j and 6k showed the similar binding conformations of horseshoe-shape as the traditional NNRTIs (Fig. 3) . The biphenyl group fitted into the tunnel site of NNIBP, exhibiting the positive face-to-face pep stacking interactions, supporting its improved adaptability with the aromatic residues (e.g., Tyr181, Tyr188 and Trp229). The nitrogen of the central ring and NH linker of these two compounds were involved in the crucial hydrogen-bonding interactions with the amide backbone of Lys101. The p-cyanoaniline extended to a solvent-exposed region of NNIBP surrounded by residues such as His235, Pro236 and Try318. The R substituents at the 6-position of DATA in compounds 5j and 6k occupied the entrance channel composed by Val106, Glu138 and Val179 residues. It is noteworthy that the 3-hydroxyl group attached to the pyrrole ring of the most active compound 6k even extended outside of the entrance channel, which might be associated with its better biological activity (Fig. 3) .
Although the most active inhibitors share similar binding conformations in the hydrogen-bonding and pep stacking interactions with RT ( Fig. 3) , the less active inhibitors showed different binding conformations with NNIBP (Fig. 4) . The interaction between compound 5b with NNIBP still involved two Scheme 1 Reagents and conditions: (i) NaH, THF, 0 C-r.t., or DIPEA, THF, reflux, 70%-80%; (ii) various substituted amines, K 2 CO 3 or DIPEA, THF, r.t., 2e5 h, 60%e75%. hydrogen bonds and the pep stacking effect between the biphenyl group and the groove site of NNIBP. Differently, the tetrahydropyranyl-amino side chain at the C6-position of the compound 5b pointed towards Pro236 pocket and the aromatic cyanophenyl ring was located close to the entrance channel of RT. The inverted conformations of the two compounds could explain the biological activity different from the more active compounds 5j and 6k. The interaction between the less inactive compound 5k with NNIBP involved no hydrogen bond while keeping the pep stacking effect. Therefore, the predicted binding modes of the less active compounds were similar in their conformations, with the substituents (R-) at the C6-position of DATAs protruding to the solvent exposed area instead of the 4-cyanoanaline group. The above analysis suggested the newly designed DATAs improved the positional adaptability, leading to their higher antiviral activity. Finally, molecular dynamic (MD) simulations were carried out to examine the binding stability of the active compounds 5j and 6k with RT using GROMACS 5.0 35 . General procedures about the MD are described in the supporting material. The initial and final binding modes of compound 5j and 6k with the low root-mean square deviation (RMSD) between the energy-minimized average structures were obtained. Both compounds (5j and 6k) bound with HIV-1 RT via the biphenyl moiety accommodating stability in the hydrophobic binding pocket formed by Phe227, Tyr181 and Trp229 (Fig. 5 ). Analysis diagram of MD trajectories for ligand 5j (left) and ligand 6k (right) in complex with WT HIV-RT was also provided in the supporting material with a normal distribution of RMSD values for both the protein and ligands 5j and 6k (Supporting Information Fig. S2 ).
Conclusions
In summary, a series of novel DATAs were designed and synthesized with the purpose to improve the positional adaptability with HIV-1 RT. These new target molecules shared the following three main structure features: various side chains on 6-position to occupy the entrance channel, 4-cyanobiphenyl on 4-position to strength the hydrophobic interaction with the tunnel site and 4-cyanoaniline on the 2-position of DATA to occupy the solventeprotein interfere. All the target compounds could inhibit HIV-1 in MT-4 cells with EC 50 values in the nanomolar range, among which the two most potent compounds 5j and 6k showed single-digit nanomolar activity comparable to ETR. These two compounds also showed potency against most of the HIV-1 mutant strains, among which 5j also exhibited improved activity against the double mutants. The enzymatic assay supported that these new DATAs could specifically target HIV-1 RT NNIBP instead of RNase H. Molecular simulation research also predicted the binding modes for the compounds, explaining their biological activity. The PK and metabolic studies provided future directions for structural optimizations of DATAs.
Experimental
Chemistry
Chemical reagents and solvents were purchased from the commercial sources as the analytical grade, which were used without further purification. All air-sensitive reactions were run under a nitrogen atmosphere. All solvents were purchased from Sinopharm Group Co. Company (Shanghai, China). All reagents were purchased from Bide Pharmatech Ltd. Company (Shanghai, China), except for PdCl 2 was purchased from Energy Chemical Ltd. Company (Shanghai, China). All the reactions were monitored by TLC on the re-coated silica gel G (HSGF254) plates purchased from Yantai Jiangyou Silica Gel Development Co. Ltd. (Yantai, China) at 254 nm under a UV lamp from Shanghai Hele Analytical Instrument Co., Ltd. (Shanghai, China) using ethyl The double mutant strain (RES056 is referred to K103N/Y181C). The concentration unit is mg/mL.
acetate/n-hexane as the eluent. Flash column chromatography was performed on glass column packed with silica gel (200e300 mesh) purchased from Qingdao Marine Chemical Plant (Qingdao, China) using ethyl acetate/n-hexane as the eluent. Melting points were measured on an SGW X-1 microscopic melting point apparatus from Shanghai Precision Scientific Instrument Co., Ltd.
(Shanghai, China). 1 H NMR and 13 C NMR spectra were recorded on a Bruker AV400 MHz spectrometer (Zurich, Switzerland) in DMSO-d 6 . Chemical shifts were reported in d (ppm) units relative to the internal standard tetramethylsilane (TMS). Mass spectra and HRMS were obtained on a Waters Quattro Micromass instrument (Manchester, England) and Bruker Compact instrument (Bremen, German), respectively, using electrospray ionization (ESI) techniques. The purities of the target compounds were !95%, measured by HPLC, performed on an Agilent 1200 HPLC system (Waldbronn, German) with UV detector (Waldbronn) and Agilent Eclipse Plus C18 column (Waldbronn, 150 mm Â 4.6 mm, 5 mm), eluting with a mixture of solvents H 2 O (A) and CH 3 CN (B) from VA:VB Z 90:10 to 10:90. Peaks were detected at l Z 254 nm with a flow rate of 1.0 mL/min.
To a solution of compound 3a (2.23 g, 10.0 mmol) and NaH (1.1 equiv) in dry tetrahydrofuran (THF, 20 mL) compound 3b (1.0 equiv.) was slowly added at 0 C. The mixture warmed to room temperature and stirred for 3 h. Then the mixture was poured into crushed ice, which was filtered to give a filter cake. The crude product was dried before being recrystallized from ethyl acetate/ petroleum ether (EA/PE) to afford pure 4a. 
Preparation of 4ʹ-((
To a solution of compound 3a (2.23 g, 10.0 mmol) and diisopropyl ethylamine (DIPEA, 1.1 equiv) in dry THF (20 mL), compound 3b-1 (1.0 equiv.) was slowly added at room temperature. Then the mixture refluxed for 3 h. The mixture cooled to room temperature and poured into crushed ice, filtered and the filter cake was dried. 
General procedure for preparing the target compounds 5ae5k and 6ae6n
To a suspension of 14 or 15 (0.50 mmol) and DIPEA (2.2 equiv) in THF (10 mL) were added with various substituted amines (1.0 equiv.). The reaction mixtures were then refluxed until the TLC monitoring test show the completion. The reaction mixtures were then concentrated and extracted with EA (10 mL Â 3). The combined extracts were dried over anhydrous Na 2 SO 4 and concentrated under vacuum to give the crude products, which were purified by flash column chromatography and recrystallized from EA/PE to afford the target compounds 5ae5k or 6ae6n. 55 (m, 1H, NH), 8.68 (s, 1H, NH) 
4ʹ-((4-((4-Cyanophenyl)amino)-6-((tetrahydro-2H-pyran-4-yl)amino)-1,3,5-triazin-2-yl)oxy)-3ʹ,5ʹ-dimethyl-[1,1ʹ-biphenyl]-4-carbonitrile (5b
Methyl (4-((4ʹ
-cyano-3,5-dimethyl-[1,1ʹ-biphenyl]-4-yl) oxy)-6-((4-cyanophenyl)-amino)-1,3,5-triazin-2-yl)-L-prolinate (5d4.1.3.8. 4ʹ-((4-((4-Cyanophenyl)amino)-6-(3-hydroxypyrrolidin- 1-yl)-1,3,5-triazin-2-yl)-oxy)-3ʹ,5ʹ-dimethyl-[1,1ʹ-biphenyl]-4- carbonitrile (5h
4ʹ-((4-((4-
Cyanophenyl)amino)-6-(4-hydroxypiperidin- 1-yl)-1,3,5-triazin-2-yl)-oxy)-3ʹ,5ʹ-dimethyl-[1,1ʹ-biphenyl]-4- carbonitrile (5i4 . 1 . 3 . 1 0 . 4 ʹ -( ( 4 -( ( 4 -C y a n o p h e n y l ) a m i n o ) -6 -( ( 2 - morpholinoethyl)amino)-1,3,5-triazin-2-yl)-oxy)-3ʹ,5ʹ-dimethyl- [1,1ʹ-biphenyl]-4-carbonitrile (5j4.1.3.17. Methyl (4-((4ʹ-cyano-3,5-dimethyl-[1,1ʹ-biphenyl]-4- yl)amino)-6-((4-cyanophenyl)amino)-1,3,5-triazin-2-yl)-L-proli- nate (6f
Cyanophenyl)amino)-6-(2-(hydroxymethyl) pyrrolidin-1-yl)-1,3,5-triazin-2-yl)amino)-3ʹ,5ʹ-dimethyl-[1,1ʹ- biphenyl]-4-carbonitrile (6j
Other protocols
Other experimental method including biological testing methods and molecular dynamic methods are described in Supporting Information associated with this article.
